Dimerix Ltd (DXB) - Total Assets
Based on the latest financial reports, Dimerix Ltd (DXB) holds total assets worth AU$91.18 Million AUD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Dimerix Ltd - Total Assets Trend (1989–2025)
This chart illustrates how Dimerix Ltd's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Dimerix Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Dimerix Ltd's total assets of AU$91.18 Million consist of 79.2% current assets and 20.8% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$68.28 Million | 74.9% |
| Accounts Receivable | AU$3.64 Million | 4.0% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$117.64K | 0.1% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (1989–2025)
This chart illustrates how Dimerix Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dimerix Ltd's current assets represent 79.2% of total assets in 2025, an increase from 21.7% in 1989.
- Cash Position: Cash and equivalents constituted 74.9% of total assets in 2025, up from 1.2% in 1989.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1989.
- Asset Diversification: The largest asset category is cash and equivalents at 74.9% of total assets.
Dimerix Ltd Competitors by Total Assets
Key competitors of Dimerix Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Zelluna ASA
OL:ZLNA
|
Norway | Nkr103.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
|
China | CN¥9.09 Billion |
Dimerix Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.26 | 9.49 | 3.95 |
| Quick Ratio | 3.26 | 9.49 | 3.91 |
| Cash Ratio | 3.08 | 6.58 | 2.96 |
| Working Capital | AU$50.02 Million | AU$28.55 Million | AU$7.76 Million |
Dimerix Ltd - Advanced Valuation Insights
This section examines the relationship between Dimerix Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.44 |
| Latest Market Cap to Assets Ratio | 1.84 |
| Asset Growth Rate (YoY) | 184.2% |
| Total Assets | AU$91.18 Million |
| Market Capitalization | $167.80 Million USD |
Valuation Analysis
Above Book Valuation: The market values Dimerix Ltd's assets above their book value (1.84x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Dimerix Ltd's assets grew by 184.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Dimerix Ltd (1989–2025)
The table below shows the annual total assets of Dimerix Ltd from 1989 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$91.18 Million | +184.23% |
| 2024-06-30 | AU$32.08 Million | +80.65% |
| 2023-06-30 | AU$17.76 Million | +7.64% |
| 2022-06-30 | AU$16.50 Million | +75.11% |
| 2021-06-30 | AU$9.42 Million | -9.32% |
| 2020-06-30 | AU$10.39 Million | +110.28% |
| 2019-06-30 | AU$4.94 Million | -31.99% |
| 2018-06-30 | AU$7.26 Million | +152.97% |
| 2017-06-30 | AU$2.87 Million | +13.72% |
| 2016-06-30 | AU$2.53 Million | -14.94% |
| 2015-06-30 | AU$2.97 Million | +144.61% |
| 2014-06-30 | AU$1.21 Million | -31.13% |
| 2014-04-30 | AU$1.76 Million | +0.50% |
| 2013-06-30 | AU$1.75 Million | +44.40% |
| 2012-06-30 | AU$1.21 Million | -23.81% |
| 2011-06-30 | AU$1.59 Million | -0.79% |
| 2010-06-30 | AU$1.61 Million | +316.92% |
| 2009-06-30 | AU$385.33K | -84.26% |
| 2008-06-30 | AU$2.45 Million | -39.86% |
| 2007-06-30 | AU$4.07 Million | +34.01% |
| 2006-06-30 | AU$3.04 Million | -71.12% |
| 2005-06-30 | AU$10.52 Million | +475.65% |
| 2004-06-30 | AU$1.83 Million | +50.28% |
| 2003-06-30 | AU$1.22 Million | -35.67% |
| 2002-06-30 | AU$1.89 Million | -17.01% |
| 2001-06-30 | AU$2.28 Million | -71.17% |
| 2000-06-30 | AU$7.90 Million | -13.37% |
| 1999-06-30 | AU$9.12 Million | -5.86% |
| 1998-06-30 | AU$9.69 Million | +328.61% |
| 1997-06-30 | AU$2.26 Million | +0.77% |
| 1996-06-30 | AU$2.24 Million | +13.25% |
| 1995-06-30 | AU$1.98 Million | -2.56% |
| 1994-06-30 | AU$2.03 Million | +24.27% |
| 1993-06-30 | AU$1.64 Million | +40.91% |
| 1992-06-30 | AU$1.16 Million | +1.04% |
| 1991-06-30 | AU$1.15 Million | -33.47% |
| 1990-06-30 | AU$1.73 Million | -3.03% |
| 1989-06-30 | AU$1.78 Million | -- |
About Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is… Read more